Basic information Safety Supplier Related

pyripyropene A

Basic information Safety Supplier Related

pyripyropene A Basic information

Product Name:
pyripyropene A
Synonyms:
  • pyripyropene A
  • FO 1289A
  • 2H,11H-Naphtho[2,1-b]pyrano[3,4-e]pyran-11-one, 3,6-bis(acetyloxy)-4-[(acetyloxy)methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-9-(3-pyridinyl)-, (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-
  • Pyripyropene A, ACAT2 inhibitor
CAS:
147444-03-9
MF:
C31H37NO10
MW:
583.63
Mol File:
147444-03-9.mol
More
Less

pyripyropene A Chemical Properties

Melting point:
153-154℃
Boiling point:
690.8±55.0 °C(Predicted)
Density 
1.33±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C, protect from light, stored under nitrogen
solubility 
DMSO: Soluble; Methanol: Soluble
pka
11.72±0.70(Predicted)
form 
White to brown powder.
color 
Pale pink to rusty brown
More
Less

pyripyropene A Usage And Synthesis

Uses

Pyripyropene A exhibits insecticidal properties and a useful compound for developing agrichemicals.

Definition

ChEBI: A sesquiterpenoid that consists of (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(acetoxymethyl)-12-hydroxy-4,6a,12b-trimethyl-11-o o-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diol in which the hydrogens of the 3- and 6-hydroxy functions are substituted by acetyl groups.

in vivo

Pyripyropene A (10-50 mg/kg per day; p.o; 12 weeks) reduces the levels of plasma cholesterol, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) and hepatic cholesterol content in apolipoprotein E-knockout mice. And Pyripyropene A-treated mice display reduction of atherogenic lesion areas in the aortae and heart[3].
? Pyripyropene A inhibits the hepatic e acyl–coenzyme A:cholesterol acyltransferase 2? (ACAT2) activity in vivo[3].
? Pyripyropene A displays a half-life (t1/2) of 0.693/λ, where λ represented the terminal slope of the log-linear portion of concentration time profile[4].

Animal Model:Male C57BL/6 mice[2]
Dosage:0 mg/kg, 1 mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg
Administration:Oral administration; daily; for 12 weeks
Result:Reduced atherogenic lesion areas in the aortae and heart.
Animal Model:9-week old male ICR mice (pharmacokinetic analysis)[4]
Dosage:5 mg/kg ,10 mg/kg
Administration:Oral administration
Result:t1/2 = 0.693/λ

storage

+4°C

pyripyropene ASupplier

Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939
Email
shenlinxing@macklin.cn
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696，15000506266 15000506266
INTERCHEMIE NANJING PHARMATECH CO., LTD
Tel
13656237714 13656237714;
Email
xiaokunfu@kyyykj.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
More
Less

pyripyropene A(147444-03-9)Related Product Information